Failed early
Abatacept: reduce relapses and new lesions in relapsing MS
relapsing MS · T-cell co-stimulation / cytokine targeting
Controlled phase 2 trials were negative.
- Trials
- 2
- Running now
- 0
- Controlled phase 2/3 trials
- 1
- People in controlled trials
- 65
Deciding trials (phase 2): 0 met, 1 did not.
Other linked trials: 1
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Human genetics
Genes linked to MS that these medicines act on: CD86
Trials
Phase 2 · 2010 · Placebo-controlled · MSFT-NCT01116427
Other linked trials: 1
These linked trials do not set the status.
- Safety of RG2077 in Patients With Multiple SclerosisResult in a paper, not read yet
Phase 1 · 2003 · Not randomised
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-27First listed as Failed early
Related hypotheses
- Laquinimod: protect nerve tissue in relapsing MS
- Laquinimod: slow disability worsening in relapsing MS
- Abatacept: reduce relapses and new lesions in relapsing and progressive MS
- Daclizumab: reduce relapses and new lesions in relapsing MS
- Dapirolizumab pegol: reduce relapses and new lesions in relapsing MS
- Frexalimab: reduce relapses and new lesions in relapsing MS
- Laquinimod: reduce relapses and new lesions in relapsing MS
- Secukinumab: reduce relapses and new lesions in relapsing MS
- Ustekinumab: reduce relapses and new lesions in relapsing MS
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error